Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact Contact Barchart
Market:
Karuna Therapeutics Inc (KRTX)
Karuna Therapeutics Inc (KRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q1 Zacks - Fri May 5, 9:54AM CDT

Karuna Therapeutics (KRTX) reports encouraging first-quarter 2023 results. The company beats estimates for earnings and sales.

ADAP : 0.5422 (+8.44%)
SPRO : 1.1700 (+2.63%)
KRTX : 196.53 (+2.78%)
LSTA : 2.25 (+2.74%)
Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates Business Wire - Thu May 4, 5:30AM CDT

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions,...

KRTX : 196.53 (+2.78%)
Karuna Therapeutics to Present at Upcoming Investor Conferences Business Wire - Tue May 2, 5:30AM CDT

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions,...

KRTX : 196.53 (+2.78%)
3 Biotech Buyout Targets to Watch Motley Fool - Sat Apr 29, 7:25AM CDT

The trio all have late-stage therapies with blockbuster potential.

ETNB : 8.40 (+4.48%)
KRTX : 196.53 (+2.78%)
MORF : 24.41 (+3.00%)
PureTech Announces Annual Results for Year Ended December 31, 2022 Business Wire - Fri Apr 28, 1:00AM CDT

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its results for the year ended December 31, 2022, as well as its cash balance as of the first quarter...

PRTC : 19.52 (-2.16%)
PRTC.LN : 152.000 (+0.26%)
BIIB : 234.64 (+0.24%)
KRTX : 196.53 (+2.78%)
VOR : 1.9200 (+3.78%)
AKLI : 0.4900 (-1.41%)
Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023 Business Wire - Thu Apr 20, 5:30AM CDT

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions,...

KRTX : 196.53 (+2.78%)
Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares Business Wire - Fri Mar 24, 3:01PM CDT

Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological...

KRTX : 196.53 (+2.78%)
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval Zacks - Thu Mar 23, 12:51PM CDT

Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.

BIIB : 234.64 (+0.24%)
GILD : 77.65 (+1.37%)
INCY : 54.02 (-0.59%)
ALT : 3.57 (+12.97%)
KRTX : 196.53 (+2.78%)
Karuna Therapeutics to Present at the Stifel 2023 CNS Days Business Wire - Thu Mar 23, 5:30AM CDT

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions,...

KRTX : 196.53 (+2.78%)
Why Shares of Karuna Therapeutics Were Up Wednesday Motley Fool - Wed Mar 22, 11:24AM CDT

The clinical-stage biotech announced positive trial results for its lead therapy.

KRTX : 196.53 (+2.78%)

Barchart Exclusives

5 Reasons to Buy First Solar Stock Now Barchart - 1 hour ago
It's been a tough year for solar stocks in 2023, but First Solar could be a compelling buy at current levels. Here's why. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot